Cortexyme has added $11.3m to its initial public offering, after the Pfizer, Takeda and Alphabet-based Alzheimer’s therapy developer raised $75m last week.

Cortexyme, the US-based degenerative disease drug developer backed by internet technology conglomerate Alphabet and pharmaceutical firms Pfizer and Takeda, formally closed its initial public offering at approximately $86.3m on Monday. The company secured $75m last week when it issued more than 4.4 million shares priced in the middle of the IPO’s $16 to $18 range,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.